Clinical application of docetaxel improved new drug in Zhongsheng pharmaceutical

Source: Sina Pharmaceutical News on the evening of May 23, 2018, Guangdong Zhongsheng Pharmaceutical Co., Ltd announced that the company recently received the approval document for clinical trial of drug for injection of docetaxel polymer micelles issued by CFDA Docetaxel polymer micelles for injection is an improved new drug (chemical 2.2) of docetaxel, a basic chemotherapy and antitumor drug developed by Zhongsheng pharmaceutical industry Docetaxel is a kind of microtubule inhibitor It can promote the formation of stable nonfunctional microtubule bundles and destroy the mitosis of tumor cells by strengthening the polymerization of microtubule proteins and inhibiting the depolymerization of microtubules Docetaxel is mainly applied to breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck squamous cell carcinoma, etc The existing preparations have been used in Twain * -80 and anhydrous alcohol, which have toxic and side effects such as allergic reaction and fluid retention during clinical use, which limits their clinical application The docetaxel polymer micelle for injection developed by Zhongsheng Pharmaceutical Co., Ltd is a core-shell polymer micelle with core-shell structure prepared by physical encapsulation of docetaxel with MPEG PDLLA Compared with the existing preparations, the * has the function of passive targeting and synergistic attenuation, and can also avoid the side effects of allergic reactions and fluid retention of the existing preparations, and has better clinical safety Docetaxel is a broad-spectrum anti-tumor drug It has always been the first-line treatment for breast cancer, non-small cell lung cancer, ovarian cancer and other cancers It is also a national medical insurance product with a large clinical demand The products on the market in China mainly include tersotti, aisu, dopafi, etc According to the database of chemical terminal competition pattern of China's urban public hospitals on minenet, the total sales of docetaxel injection top 20 brands from 2013 to 2016 were 3.745 billion yuan, 3.95921 billion yuan, 4.40453 billion yuan and 4.4302.4 billion yuan, increasing year by year Up to now, there is no docetaxel micelle product on the market in China The docetaxel polymer micelle developed by Zhongsheng Pharmaceutical Co., Ltd is the second micelle preparation with clinical approval in China.